Merck Patent Gmbh

Cancer Research Technology Limited

Emd Lexigen Research Center Corp.

Emd Serono Research Center, Inc.

Pascal Andre Stein

Kin-Ming Lo

Stephen D Gillies

Michael Super

Jonathan Harry Davis

Gordon D Webster

Suzanne P McKenzie

Jonathan H Davis

Suzanne P Mckenzie

Anti-CD19 B4 antibodies with modified variable regions are disclosed. The modified anti-CD19 variable region polypeptides have alterations to one or more framework regions or complementarity determining regions of the heavy chain variable region or light chain variable region, thereby to reduce a T-cell response.

Anti-CD19 antibodies with reduced immunogenicity

Methods of use of anti-CD19 antibodies with reduced immunogenicity

Disclosed are antibody fusion proteins with a modified FcRn binding site and nucleic acid molecules encoding them. The antibody fusion protein include two polypeptide chains, wherein the first polypeptide chain includes a biologically active molecule linked to at least a portion of an immunoglobulin constant region. The second polypeptide chain includes at least a portion of an immunoglobulin constant region. One of the polypeptide chains includes a mutation in the FcRn binding site that reduces binding to FcRn. Also disclosed are methods of producing the fusion proteins and methods of using the fusion proteins for treating diseases and conditions alleviated by the administration of the fusion proteins.

Antibody fusion proteins with a modified FcRn binding site

Modified interleukin-12 (IL-12) p40 polypeptides are disclosed. The modified polypeptides have alterations in the IL-12p40 subunit to eliminate the protease site between positions Lys260 and Arg261. The modified IL-12p40 polypeptides according to the invention have improved stability compared to wild-type mature human IL-12p40 polypeptides.

Nucleic acids encoding interleukin-12P40 variants with improved stability

The invention provides cytokine fusion proteins with an increased therapeutic index, and methods to increase the therapeutic index of such fusion proteins. The fusion proteins of the invention are able to bind to more than one type of cytokine receptor expressed on cells and also bind to more than one cell type. In addition, the fusion proteins of the invention exhibit a longer circulating half-life in a patient's body than the corresponding naturally occurring cytokine.

DNA encoding IL-2 fusion proteins with modulated selectivity

Cancer treatments including administering IL-2 fusion proteins with modulated selectivity

IL-2 fusion proteins with modulated selectivity

Growing community of inventors

Boston, MA, United States of America

Pascal Andre Stein